UroGen Pharma to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022Business Wire • 05/03/22
UroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder CancerBusiness Wire • 03/29/22
UroGen Pharma Ltd.'s (URGN) CEO Liz Barrett on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/21/22
UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 03/21/22
UroGen Secures $100 Million Non-Dilutive Term Loan Financing with Pharmakon Advisors Allowing Funding to Cash Flow BreakevenBusiness Wire • 03/08/22
UroGen Pharma to Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 10, 2022Business Wire • 03/04/22
UroGen Submits Investigational New Drug Application Supporting Planned Phase 1 Clinical Study of UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder CancerBusiness Wire • 03/01/22
UroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare ConferenceBusiness Wire • 02/28/22
UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by PatientsBusiness Wire • 02/10/22
UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerBusiness Wire • 02/03/22
First Patient Dosed in UroGen Pharma's Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)Business Wire • 12/21/21
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/15/21
UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 11/15/21
UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight EventBusiness Wire • 11/10/21
Urogen Pharma (URGN) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 11/01/21
The Journal of Urology Publishes Results of UroGen Pharma's Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)Business Wire • 10/05/21
UroGen Pharma to Present at the 2021 Cantor Virtual Global Healthcare ConferenceBusiness Wire • 09/23/21
UroGen Pharma Presents Data Showcasing Novel Clinical Data at 2021 American Urological Association (AUA) Annual MeetingBusiness Wire • 09/13/21
UroGen Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceBusiness Wire • 09/10/21
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/07/21